Advertisement
Combined treatment with glecaprevir and pibrentasvir is highly effective in treating chronic hepatitis C virus genotype-1 infections that failed to respond to direct-acting antiviral therapy

Option Found for Retreatment of Chronic Hep C Infection

0
Glecaprevir + pibrentasvir effective for those who previously failed direct-acting antiviral treatment
More than one-third of Americans have prediabetes

CDC: Many Americans May Have Prediabetes and Not Know It

0
AMA, CDC launch a campaign to raise awareness about prediabetes
Rising drug spending in the United States is being fueled by expensive name-brand prescription medicines

Name-Brand Medications Driving Spike in U.S. Drug Spending

0
Greatest costs for Humira, Remicade, Enbrel, Novolog, and Neulasta
The American College of Foot and Ankle Surgeons and the American Association of Nurse Practitioners-Orthopedics Specialty Practice Group have issued a new joint clinical consensus statement on the etiology

Consensus Statement Issued on Management of Foot, Ankle Gout

0
Risk for gouty flares increased with use of thiazide diuretics, excessive alcohol intake
For patients with prediabetes who are randomly assigned to interventions

Changes in Risk Indicators of MetS Severity Tied to T2DM Risk

0
For patients with prediabetes, changes in risk indicators during intervention tied to T2DM, CVD risk
A pharmacist-led intervention has the potential to reduce prescriptions for inappropriate medication in older adults

Pharmacist-Led Effort Cuts Inappropriate Rx in Older Adults

0
Intervention included educational deprescribing information to patients, physicians
More than one-third of pediatric patient safety reports in 2012 to 2017 that were related to electronic health record use were attributed to usability issues

One-Third of Peds Medication Errors Due to Usability Issues

0
EHR usability issues contribute to 36 percent of med errors; 18.8 percent may have caused harm
Denosumab

Denosumab Promising for TDT-Induced Osteoporosis Treatment

0
Higher percentage increase of L1 to L4 and wrist bone mineral density with DMN, reduction in pain
Treatment with dapagliflozin is noninferior to placebo for major adverse cardiovascular events among patients with type 2 diabetes with or at risk for atherosclerotic cardiovascular disease

AHA: Dapagliflozin Noninferior to Placebo for MACE in T2DM

0
Treatment resulted in lower HF hospitalization rate in patients with, without atherosclerosis
Omega-3 fatty acids and vitamin D do not significantly reduce major cardiovascular events or cancer incidence

AHA: Limited Benefit for n-3 Fatty Acids in CVD, Cancer Prevention

0
Second study shows no significant results for vitamin D supplementation versus placebo